James T. Lynch

1.8k total citations · 1 hit paper
27 papers, 1.1k citations indexed

About

James T. Lynch is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, James T. Lynch has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 6 papers in Hematology and 5 papers in Oncology. Recurrent topics in James T. Lynch's work include Histone Deacetylase Inhibitors Research (9 papers), Epigenetics and DNA Methylation (8 papers) and Acute Myeloid Leukemia Research (6 papers). James T. Lynch is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Epigenetics and DNA Methylation (8 papers) and Acute Myeloid Leukemia Research (6 papers). James T. Lynch collaborates with scholars based in United Kingdom, United States and Japan. James T. Lynch's co-authors include Tim C. P. Somervaille, William J. Harris, Gary J. Spencer, James R. Hitchin, Xu Huang, Filippo Ciceri, Yaoyong Li, Allan M. Jordan, Donald Ogilvie and Brigit Greystoke and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

James T. Lynch

25 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

2012 432 citations William J. Harris, Xu Huang et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James T. Lynch United Kingdom	15	935	255	137	122	98	27	1.1k
Louise Howell United Kingdom	9	812 0.9×	199 0.8×	103 0.8×	92 0.8×	96 1.0×	15	967
Alla Dolnikov Australia	16	486 0.5×	236 0.9×	242 1.8×	106 0.9×	152 1.6×	49	757
Sven Fraterman Germany	11	973 1.0×	101 0.4×	131 1.0×	121 1.0×	55 0.6×	11	1.2k
W. Brian Dalton United States	14	857 0.9×	141 0.6×	185 1.4×	224 1.8×	56 0.6×	32	1.1k
Salam A. Assi United Kingdom	17	838 0.9×	423 1.7×	80 0.6×	39 0.3×	156 1.6×	33	1.0k
Sergei Vatolin United States	11	783 0.8×	82 0.3×	68 0.5×	228 1.9×	133 1.4×	18	901
Cecilia Grimaldi Italy	13	517 0.6×	113 0.4×	119 0.9×	32 0.3×	75 0.8×	17	723
Andrea Basile Italy	17	591 0.6×	232 0.9×	299 2.2×	49 0.4×	320 3.3×	26	1.1k
Dilshad H. Khan Canada	12	732 0.8×	78 0.3×	163 1.2×	52 0.4×	90 0.9×	22	887
Miao-Chia Lo United States	15	560 0.6×	164 0.6×	47 0.3×	64 0.5×	54 0.6×	19	693

Countries citing papers authored by James T. Lynch

Since Specialization

Citations

This map shows the geographic impact of James T. Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James T. Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James T. Lynch more than expected).

Fields of papers citing papers by James T. Lynch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James T. Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James T. Lynch. The network helps show where James T. Lynch may publish in the future.

Co-authorship network of co-authors of James T. Lynch

This figure shows the co-authorship network connecting the top 25 collaborators of James T. Lynch. A scholar is included among the top collaborators of James T. Lynch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James T. Lynch. James T. Lynch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lingadahalli, Shreyas, Tunç Morova, Chia-Chi Flora Huang, et al.. (2025). Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer. Communications Biology. 8(1). 169–169. 1 indexed citations

Smith, Julian R., Jelena Urosevic, S. Breanndan Moore, et al.. (2024). 146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies. European Journal of Cancer. 211. 114668–114668.

Lynch, James T., Shaun Moore, Iván del Barco Barrantes, et al.. (2023). Abstract 6272: AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours. Cancer Research. 83(7_Supplement). 6272–6272. 2 indexed citations

Xu, Wendan, Philipp Berning, Tabea Erdmann, et al.. (2022). mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 37(1). 178–189. 18 indexed citations

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2018). Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors. Molecular Cancer Therapeutics. 17(11). 2309–2319. 18 indexed citations

Maiqués-Díaz, Alba, Gary J. Spencer, James T. Lynch, et al.. (2018). Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Reports. 22(13). 3641–3659. 137 indexed citations

Maiqués-Díaz, Alba, James T. Lynch, Gary J. Spencer, & Tim C. P. Somervaille. (2018). LSD1 inhibitors disrupt the GFI1 transcription repressor complex. Molecular & Cellular Oncology. 5(4). e1481813–e1481813. 19 indexed citations

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2017). Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clinical Cancer Research. 23(24). 7584–7595. 24 indexed citations

Somerville, Tim D.D., Daniel H. Wiseman, Gary J. Spencer, et al.. (2015). Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia. Cancer Cell. 28(3). 329–342. 52 indexed citations

10.

Somerville, Tim D.D., Xu Huang, James T. Lynch, Gary J. Spencer, & Tim C. P. Somervaille. (2014). FOXC1 Is Derepressed to Functional Effect in Human Acute Myeloid Leukemia. Blood. 124(21). 889–889.

11.

Keune, Willem‐Jan, Andrew H. Sims, D. I. Jones, et al.. (2013). Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression. Cancer Research. 73(23). 6913–6925. 40 indexed citations

12.

Lynch, James T., Tim D.D. Somerville, Gary J. Spencer, Xu Huang, & Tim C. P. Somervaille. (2013). TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells. Cell Death and Disease. 4(4). e573–e573. 10 indexed citations

13.

Lynch, James T., Mark Cockerill, James R. Hitchin, Daniel H. Wiseman, & Tim C. P. Somervaille. (2013). CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. Analytical Biochemistry. 442(1). 104–106. 43 indexed citations

14.

Huang, Xu, Gary J. Spencer, James T. Lynch, et al.. (2013). Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells. Leukemia. 28(5). 1081–1091. 33 indexed citations

15.

Huang, Xu, James T. Lynch, James R. Hitchin, et al.. (2012). The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells. Cancer Cell. 21(6). 856–856. 15 indexed citations

16.

Harris, William J., Xu Huang, James T. Lynch, et al.. (2012). The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells. Cancer Cell. 21(4). 473–487. 432 indexed citations breakdown →

17.

Lynch, James T., William J. Harris, & Tim C. P. Somervaille. (2012). LSD1 inhibition: a therapeutic strategy in cancer?. Expert Opinion on Therapeutic Targets. 16(12). 1239–1249. 98 indexed citations

18.

Lynch, James T., et al.. (2010). The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Molecular Cancer. 9(1). 38–38. 29 indexed citations

19.

Lynch, James T., et al.. (2008). Cross Talk of Signaling Pathways in the Regulation of the Glucocorticoid Receptor Function. Molecular Endocrinology. 22(6). 1331–1344. 90 indexed citations

20.

Lynch, James T., J.B. Hawkyard, & W. Johnson. (1970). Laboratory Scale Experiments into Cavity and Crater Formation by High Explosive Charges. Journal of Mechanical Engineering Science. 12(5). 339–353. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact